Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Related Questions
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
Do you routinely use anti-resorptive medications in patients who have osteoporosis and longstanding hypoparathyroidism?
Under what circumstances would you choose palopegteriparatide over teriparatide in patients with chronic hypoparathyroidism?
Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
How long should a patient be treated with a bisphosphonate after a course of an anabolic medication has been completed?
What is the utility of near-infrared autofluorescence (NIRAF) imaging during parathyroid surgery?
